Effect of prothrombin Concentrate complex on reverse of bleeding due to Rivaroxaba
Phase 1
Recruiting
- Conditions
- Abnormal finding of blood chemistry, major bleeding.Abnormal finding of blood chemistry, major bleeding due to coagulopathyR79.9 Abno
- Registration Number
- IRCT20091012002582N20
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
All patients who admitted in ICU with major bleeding and Life threatening related to Rivaroxaban
Exclusion Criteria
Unwillingness of the patient
Allergic to PCC
History of receiving antiplatelet drugs&NSAIDs
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method He amount of bleeding in rivaroxaban use. Timepoint: duration of ICU stay. Method of measurement: blood loss volume and hemodynamic changes.
- Secondary Outcome Measures
Name Time Method The number of units transfused and blood products. Timepoint: From the bleeding time to the stop bleeding. Method of measurement: Measure the number of units transfused and blood products.